MX2011012347A - Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria. - Google Patents

Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.

Info

Publication number
MX2011012347A
MX2011012347A MX2011012347A MX2011012347A MX2011012347A MX 2011012347 A MX2011012347 A MX 2011012347A MX 2011012347 A MX2011012347 A MX 2011012347A MX 2011012347 A MX2011012347 A MX 2011012347A MX 2011012347 A MX2011012347 A MX 2011012347A
Authority
MX
Mexico
Prior art keywords
herpes simplex
simplex virus
eliciting
compositions
methods
Prior art date
Application number
MX2011012347A
Other languages
English (en)
Inventor
Deborah Long
Jessica Flechtner
Mojca Skoberne
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of MX2011012347A publication Critical patent/MX2011012347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La infección del virus del herpes simple-2 (VHS-2) es una grave preocupación de salud. La presente descripción proporciona, inter alia, ciertas vacunas altamente efectivas y composiciones inmunogénicas contra HSV-2. Los antígenos pueden usarse terapéutica o profilácticamente.
MX2011012347A 2009-05-22 2010-05-24 Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria. MX2011012347A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18078409P 2009-05-22 2009-05-22
US23562809P 2009-08-20 2009-08-20
US24062609P 2009-09-08 2009-09-08
US24058709P 2009-09-08 2009-09-08
US30591810P 2010-02-18 2010-02-18
PCT/US2010/035998 WO2010135747A1 (en) 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (1)

Publication Number Publication Date
MX2011012347A true MX2011012347A (es) 2012-02-21

Family

ID=43126545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012347A MX2011012347A (es) 2009-05-22 2010-05-24 Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.

Country Status (17)

Country Link
US (3) US8617564B2 (es)
EP (3) EP2432504B1 (es)
JP (2) JP5771605B2 (es)
KR (1) KR101746872B1 (es)
CN (2) CN106924728B (es)
AU (1) AU2010249330B2 (es)
BR (1) BRPI1012811A2 (es)
CA (1) CA2797937C (es)
ES (1) ES2732815T3 (es)
IL (1) IL216508A (es)
MX (1) MX2011012347A (es)
MY (1) MY159500A (es)
NZ (1) NZ597182A (es)
RU (1) RU2585961C9 (es)
SG (1) SG176207A1 (es)
WO (2) WO2010135749A1 (es)
ZA (1) ZA201109444B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
US20130039947A1 (en) 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
AU2011336894B2 (en) * 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012139099A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus vaccine
CA2885693C (en) * 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2850431B1 (en) * 2012-05-16 2018-04-18 Immune Design Corp. Vaccines for hsv-2
US20140093537A1 (en) * 2012-09-30 2014-04-03 Nanobio Corporation Immunogenic compositions comprising nanoemulsion and methods of administering the same
CN103074337B (zh) * 2012-12-04 2014-07-09 昆明寰基生物芯片产业有限公司 一段单纯疱疹病毒dna序列及应用
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
CN106456805B (zh) * 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
RS62747B1 (sr) 2016-02-01 2022-01-31 Simplexia Ab Skraćeni glikoprotein g herpes simpleks virusa 2
WO2018064232A1 (en) * 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
US11160860B2 (en) 2017-04-26 2021-11-02 Merck Sharp & Dohme Corp. HSV antigenic peptides and HSV protein vaccines
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
SG11202102007UA (en) 2018-09-12 2021-03-30 Affinivax Inc Multivalent pneumococcal vaccines
US20220168415A1 (en) 2019-03-21 2022-06-02 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
JP2022525924A (ja) 2019-03-21 2022-05-20 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞コンジュゲート及びその使用
CN109943592B (zh) * 2019-04-29 2020-11-17 华中农业大学 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用
CN110724181A (zh) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 单纯疱疹病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
CN110845583A (zh) * 2019-11-18 2020-02-28 维塔恩(广州)医药有限公司 水痘带状疱疹病毒相关抗原短肽及其应用
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
WO1990013652A1 (en) 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
EP0541692B1 (en) 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
CA2164601A1 (en) 1993-06-08 1994-12-22 Kevin R. Steffy Herpes simplex virus type-2 protease
CA2169748A1 (en) 1993-08-20 1995-03-02 Anthony G. Dilella Hsv-2 ul26 gene, capsid proteins, immunoassays and protease inhibitors
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
EP0958373A4 (en) 1996-10-23 2001-11-28 American Home Prod Vaccines.
CN1324139C (zh) * 1996-10-23 2007-07-04 惠氏 疫苗
EP0948508A4 (en) 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
CA2291010A1 (en) 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
HUP0101047A3 (en) 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
BR9912671A (pt) 1998-08-07 2001-05-02 Univ Washington Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
KR100768114B1 (ko) * 1999-06-10 2007-10-17 메리알 애완 동물 및 스포츠용 동물을 위한 ｄｎａ 백신
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CA2379623C (en) 1999-09-30 2014-09-09 University Of Washington Immunologically significant herpes simplex virus antigens
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
CN1222619C (zh) 1999-12-17 2005-10-12 惠氏控股公司 增强对单纯疱疹病毒疫苗应答的疫苗及其制药应用
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6537555B2 (en) 2000-06-29 2003-03-25 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030165819A1 (en) 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
CA2417364A1 (en) 2000-07-27 2002-02-07 The Trustees Of The University Of Pennsylvania Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
EP1370283A4 (en) 2000-11-16 2004-12-15 Univ Maryland PREVENTING RECURRING VIRUS DISEASES
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
EP1528937B1 (en) 2001-06-05 2016-08-10 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2003011893A2 (en) 2001-07-31 2003-02-13 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
WO2003020108A2 (en) 2001-09-04 2003-03-13 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
US20080299140A1 (en) 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
EP2011510B1 (en) 2002-07-18 2011-01-12 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
US7267940B2 (en) 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CA2630218A1 (en) 2005-11-18 2007-08-30 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
JP2009529576A (ja) 2006-03-10 2009-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 持続感染または潜伏感染を引き起こすウイルスに対するワクチン
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
US8871223B2 (en) 2006-09-08 2014-10-28 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
WO2008140478A2 (en) 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
CN101616688B (zh) * 2006-12-28 2013-12-11 宾夕法尼亚大学理事会 单纯疱疹病毒联合亚单位疫苗及其使用方法
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2009006618A2 (en) 2007-07-05 2009-01-08 University Of Kansas Herpes simplex virus mutant icp0 protein
AU2008274887B2 (en) 2007-07-06 2013-10-31 The University Of Sydney Epitopes of herpes simplex virus
CA2725381A1 (en) * 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
AU2009266924B2 (en) 2008-07-01 2015-12-10 Genocea Biosciences, Inc. Antigen screening system
AU2009333159A1 (en) 2008-12-17 2011-08-04 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
CN102427828A (zh) 2009-03-09 2012-04-25 威廉·亨利 含具有信号肽的细菌毒素作为载体的半抗原-载体缀合物和它们在免疫原性组合物中的用途
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
US9089537B2 (en) 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
WO2011112717A1 (en) 2010-03-09 2011-09-15 Biomedical Research Models, Inc. A novel mucosal vaccination approach for herpes simplex virus type-2
JP2013545448A (ja) 2010-10-20 2013-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド クラミジア抗原及びその使用
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes

Also Published As

Publication number Publication date
US20100330112A1 (en) 2010-12-30
MY159500A (en) 2017-01-13
RU2585961C9 (ru) 2016-12-27
WO2010135749A9 (en) 2011-07-21
ES2732815T3 (es) 2019-11-26
KR20120087805A (ko) 2012-08-07
KR101746872B1 (ko) 2017-06-14
CA2797937C (en) 2020-01-14
US8617564B2 (en) 2013-12-31
IL216508A0 (en) 2012-02-29
BRPI1012811A2 (pt) 2016-03-29
US9895436B2 (en) 2018-02-20
CN102458463B (zh) 2017-01-18
SG176207A1 (en) 2011-12-29
WO2010135749A1 (en) 2010-11-25
JP5771605B2 (ja) 2015-09-02
AU2010249330B2 (en) 2015-11-05
US20180369365A1 (en) 2018-12-27
CN106924728B (zh) 2021-02-05
EP3590533A1 (en) 2020-01-08
EP2432504A1 (en) 2012-03-28
US10653771B2 (en) 2020-05-19
CA2797937A1 (en) 2010-11-25
CN102458463A (zh) 2012-05-16
JP6096839B2 (ja) 2017-03-15
RU2585961C2 (ru) 2016-06-10
NZ597182A (en) 2014-07-25
US20140227307A1 (en) 2014-08-14
IL216508A (en) 2016-08-31
EP2432504B1 (en) 2019-05-01
EP2432504A4 (en) 2013-07-31
CN106924728A (zh) 2017-07-07
JP2015178529A (ja) 2015-10-08
JP2012527486A (ja) 2012-11-08
ZA201109444B (en) 2016-09-28
WO2010135747A1 (en) 2010-11-25
AU2010249330A1 (en) 2012-01-19
RU2011147153A (ru) 2013-06-27
EP3756684A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
MX2011012347A (es) Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.
WO2012074881A3 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2009128950A3 (en) Deletion mutants of flagellin and methods of use
PH12018501602A1 (en) Subunit immersion vaccines for fish
NZ601345A (en) Combination adjuvant formulation
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
GB201009273D0 (en) Novel vaccine
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
SG10201903538YA (en) Modified virus-like particles of cmv
WO2007052058A8 (en) Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2011011186A (es) Una vacuna antituberculosis tb para evitar la reactivacion.
WO2011079073A3 (en) Herpes simplex virus vaccines
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
MY202024A (en) Novel mucosal adjuvants and delivery systems
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
NZ611531A (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
UA100710C2 (ru) Композиция для индукции иммунной реакции против вируса bluetongue (btv) у животного
MX2010013226A (es) Metodo para volver tolerogenicas celulas dendriticas mediante virus sincitial respiratorio.
UA101385C2 (ru) Иммунологическая композиция, которая в качестве адъюванты содержит сульфолипо-циклодекстрин (sl-cd) и сапонин
WO2011100408A3 (en) Serologic correlates of protection against bacillis anthracis infection
MX350718B (es) Vacuna de rinitis equina.
PH12014501688A1 (en) Influenza c virus and vaccine

Legal Events

Date Code Title Description
FG Grant or registration